Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.41 |
| ▸ | PAM | P19021 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ASAH1 | Q13510 | 3/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
| ▸ | CPT2 | P23786 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6870440 | 0.95 | CYP4F2 (0.43) | CYP4F2CYP4A11PAMHSPD1BLM | |
| SCHEMBL6870852 | 0.94 | CYP4F2 (0.42) | CYP4F2CYP4A11PAMTSHRHSPD1 | |
| SCHEMBL6863410 | 0.94 | CYP4F2 (0.42) | CYP4F2CYP4A11PAMTSHRHSPD1 | |
| SCHEMBL6873143 | 0.94 | CYP4F2 (0.42) | CYP4F2CYP4A11PAMTSHRHSPD1 | |
| SCHEMBL6870881 | 0.94 | CYP4F2 (0.42) | CYP4F2CYP4A11PAMTSHRHSPD1 | |
| SCHEMBL6871551 | 0.94 | CYP4F2 (0.42) | CYP4F2CYP4A11PAMTSHRHSPD1 | |
| SCHEMBL6872504 | 0.94 | CYP4F2 (0.42) | CYP4F2CYP4A11PAMTSHRHSPD1 | |
| SCHEMBL6872030 | 0.94 | CYP4F2 (0.42) | CYP4F2CYP4A11PAMTSHRHSPD1 | |
| SCHEMBL6874398 | 0.94 | CYP4F2 (0.42) | CYP4F2CYP4A11PAMTSHRHSPD1 | |
| SCHEMBL1038750 | 0.94 | CYP4F2 (0.36) | CYP4F2CYP4A11PAMTSHRHSPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1165633-B1 | COMPONENTS AND CATALYSTS FOR THE POLYMERIZATION OF OLEFINS | BASELL POLIOLEFINE SPA (IT) | 2004-07-14 | — | — | EP | disclosed |
| US-6716939-B2 | COMPRISING TITANIUM, MAGNESIUM, HALOGEN AND AN ELECTRON DONOR COMPOUND SELECTED FROM ESTERS OF SUBSTITUTED SUCCINIC ACIDS | BASELL POLIOLEFINE ITALIA S.P.A. (IT) | 2004-04-06 | — | — | US | disclosed |
| US-20020183575-A1 | Components and catalysts for the polymerization of olefins | BASELL POLIOLEFINE ITALIA S.P.A. (IT) | 2002-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183575-A1 | Components and catalysts for the polymerization of olefins | SCO2, ECI1, MT-CO2 | CYP4F2 138/4885CYP4A11 514/4885PAM 1410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.